BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36977982)

  • 21. Adenomatous Polyposis Coli, mismatch repair, and microsatellite instability in colorectal cancer based on different locations.
    Effendi-Y S R; Zain LH; Siregar GA; Lubis HR; Damanik HA; Laksmi LI; Chrestella J
    Acta Med Indones; 2013 Oct; 45(4):275-83. PubMed ID: 24448331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
    Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
    J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive biomarkers of colon cancer immunotherapy: Present and future.
    Hou W; Yi C; Zhu H
    Front Immunol; 2022; 13():1032314. PubMed ID: 36483562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
    Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
    BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.
    Nava Rodrigues D; Rescigno P; Liu D; Yuan W; Carreira S; Lambros MB; Seed G; Mateo J; Riisnaes R; Mullane S; Margolis C; Miao D; Miranda S; Dolling D; Clarke M; Bertan C; Crespo M; Boysen G; Ferreira A; Sharp A; Figueiredo I; Keliher D; Aldubayan S; Burke KP; Sumanasuriya S; Fontes MS; Bianchini D; Zafeiriou Z; Teixeira Mendes LS; Mouw K; Schweizer MT; Pritchard CC; Salipante S; Taplin ME; Beltran H; Rubin MA; Cieslik M; Robinson D; Heath E; Schultz N; Armenia J; Abida W; Scher H; Lord C; D'Andrea A; Sawyers CL; Chinnaiyan AM; Alimonti A; Nelson PS; Drake CG; Van Allen EM; de Bono JS
    J Clin Invest; 2018 Oct; 128(10):4441-4453. PubMed ID: 30179225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Establishment of a mutation prediction model for evaluating the efficacy of immunotherapy in renal carcinoma].
    Qin CP; Song YX; Ding MT; Wang F; Lin JX; Yang WB; DU YQ; Li Q; Liu SJ; Xu T
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):663-668. PubMed ID: 35950389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
    Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Construction and validation of a colon cancer prognostic model based on tumor mutation burden-related genes.
    Zou D; Xu T
    Sci Rep; 2024 Feb; 14(1):2867. PubMed ID: 38311637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data.
    Li M; Gao X; Wang X
    Front Immunol; 2023; 14():1090838. PubMed ID: 36911742
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CXCL11 Correlates with Immune Infiltration and Impacts Patient Immunotherapy Efficacy: A Pan-Cancer Analysis.
    Li Y; Han S; Wu B; Zhong C; Shi Y; Lv C; Fu L; Zhang Y; Lang Q; Liang Z; Yu Y; Tian Y
    Front Immunol; 2022; 13():951247. PubMed ID: 35935945
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Sun Y; Li L; Yao W; Liu X; Yang Y; Ma B; Xue D
    Front Genet; 2021; 12():762160. PubMed ID: 34795697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Establishment and Validation of a Genetic Label Associated With M2 Macrophage Infiltration to Predict Survival in Patients With Colon Cancer and to Assist in Immunotherapy.
    Xu B; Peng Z; Yan G; Wang N; Chen M; Yao X; Sun M; An Y
    Front Genet; 2021; 12():726387. PubMed ID: 34552622
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Age, sex, and specific gene mutations affect the effects of immune checkpoint inhibitors in colorectal cancer.
    Lin A; Zhang H; Hu X; Chen X; Wu G; Luo P; Zhang J
    Pharmacol Res; 2020 Sep; 159():105028. PubMed ID: 32569820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Wild-type APC predicts poor prognosis in microsatellite-stable proximal colon cancer.
    Jorissen RN; Christie M; Mouradov D; Sakthianandeswaren A; Li S; Love C; Xu ZZ; Molloy PL; Jones IT; McLaughlin S; Ward RL; Hawkins NJ; Ruszkiewicz AR; Moore J; Burgess AW; Busam D; Zhao Q; Strausberg RL; Lipton L; Desai J; Gibbs P; Sieber OM
    Br J Cancer; 2015 Sep; 113(6):979-88. PubMed ID: 26305864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD274, LAG3, and IDO1 expressions in tumor-infiltrating immune cells as prognostic biomarker for patients with MSI-high colon cancer.
    Lee SJ; Jun SY; Lee IH; Kang BW; Park SY; Kim HJ; Park JS; Choi GS; Yoon G; Kim JG
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1005-1014. PubMed ID: 29520442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients.
    Nikanjam M; Arguello D; Gatalica Z; Swensen J; Barkauskas DA; Kurzrock R
    Int J Cancer; 2020 Jun; 146(11):3087-3097. PubMed ID: 31479512
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nontruncating APC germ-line mutations and mismatch repair deficiency play a minor role in APC mutation-negative polyposis.
    Heinimann K; Thompson A; Locher A; Furlanetto T; Bader E; Wolf A; Meier R; Walter K; Bauerfeind P; Marra G; Müller H; Foernzler D; Dobbie Z
    Cancer Res; 2001 Oct; 61(20):7616-22. PubMed ID: 11606402
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases.
    Huang RSP; Haberberger J; Severson E; Duncan DL; Hemmerich A; Edgerly C; Ferguson NL; Williams E; Elvin J; Vergilio JA; Killian JK; Lin DI; Tse J; Hiemenz M; Owens C; Danziger N; Hegde PS; Venstrom J; Alexander B; Ross JS; Ramkissoon SH
    Mod Pathol; 2021 Feb; 34(2):252-263. PubMed ID: 32884129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A Case of Colon Cancer with Familial Adenomatous Polyposis Showing MSI-H and Deletion of MSH2/MSH6 Protein].
    Suzuki O; Chika N; Fukuchi M; Kumamoto K; Kumagai Y; Ishibashi K; Eguchi H; Mochiki E; Akagi K; Ishida H
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):2208-10. PubMed ID: 26805313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.